Search results
(A) Trials of 5 years of tamoxifen (n=10 645; ∼80% complied). (B) ATLAS trial of 10 years vs 5 years of tamoxifen (n=6846; ∼80% difference in tamoxifen use ). (C) Hypothetical trial of 10 years of tamoxifen vs none (with ∼80% compliance). Two-sided p values in this table relate to particular time periods; values elsewhere combine all time ...
- Tamoxifen - StatPearls - NCBI Bookshelf - National Center for ...
Tamoxifen is a selective estrogen receptor modulator (SERM)...
- Tamoxifen for prevention of breast cancer: extended long-term ... - PubMed
Background: Four previously published randomised clinical...
- Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a ...
Taking tamoxifen for the recommended 5 years reduces the...
- Tamoxifen - StatPearls - NCBI Bookshelf - National Center for ...
9 mar 2013 · Methods: In the worldwide Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, 12,894 women with early breast cancer who had completed 5 years of treatment with tamoxifen were randomly allocated to continue tamoxifen to 10 years or stop at 5 years (open control).
10 kwi 2023 · Tamoxifen is a selective estrogen receptor modulator (SERM) medication used to treat breast cancer in men and women and as a prophylactic agent against breast cancer in women.
Background: Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast cancer in healthy women at increased risk of breast cancer in the first 10 years of follow-up.
1 maj 2011 · Taking tamoxifen for the recommended 5 years reduces the risk of recurrence or contralateral breast cancer 15 years after starting treatment. It also lowers the risk of CV disease and death as a result of a CV event, particularly among those age 50 to 59 years.
12 paź 2018 · With the increase in the recurrence risk after 10 years, extended adjuvant TAM for more than 10 years probably shows significant clinical efficacy. In the process, identifying patients with high-risk recurrence is the key factor to guide treatment.
10 paź 2022 · Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of estrogen receptor–positive breast cancer: ATLAS, a randomized trial. Lancet North Am Ed 2013; 381 :805–16.
